Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07676266
PHASE1

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Sponsor: The Affiliated Hospital of Qingdao University

View on ClinicalTrials.gov

Summary

This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy

Official title: An Exploratory Clinical Study of Anti-CD20/B-cell Maturation Antigen (BCMA) Chimeric Antigen Receptor Autologous T Cell Product (C-CAR168) in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

18

Start Date

2026-07

Completion Date

2028-10

Last Updated

2026-06-30

Healthy Volunteers

No

Interventions

BIOLOGICAL

CD20/BCMA-directed CAR-T cells Autologous 2nd generation

CD20/BCMA-directed CAR-T cells, single infusion intravenously

Locations (1)

The Affiliated Hospital of Qingdao University

Qingdao, Qindao, Shandong, China